BP-42 (Toyama)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameBP-42 (Toyama)
Drug Alias Name3-butylidene-4,5-dihydroxypthalideBP 421BP 42BP 422BP-42 (Toyama) +[7] 
ClassificationSmall molecules
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsFibroblast growth factor 2 inhibitors
TargetsFibroblast growth factor 2Platelet-derived growth factor receptor
Therapy Area/IndicationsAtherosclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesToyama Medical and Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesToyama Medical and Pharmaceutical University
Active IndicationsN/A
Inactive IndicationsAtherosclerosis

Other Information

ATC CodeN/A
Related LinksN/A